Forward-Looking Safe Harbor Statement

This presentation contains forward-looking statements, including statements regarding the timing of expected launch and expected regulatory approvals for NERLYNX®. All statements other than historical facts are forward–looking statements and are based on the current expectations, forecasts and assumptions of Puma Biotechnology, Inc. (“Puma”). Forward–looking statements involve risks and uncertainties that could cause Puma’s actual results to differ materially from the anticipated results and expectations expressed in these forward-looking statements, including, but not limited to, any adverse impact on Puma’s business or the global economy and financial markets, generally, from the global COVID-19 pandemic, and the risk factors disclosed in the periodic and current reports filed by Puma with the Securities and Exchange Commission from time to time, including Puma’s Annual Report on Form 10-K for the year ended December 31, 2019, Puma’s Quarterly Report on Form 10-Q for the period ended March 31, 2020 (once filed), and subsequent reports. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and you should not rely on these forward-looking statements as representing Puma’s views as of any date subsequent to the date of this presentation. Puma assumes no obligation to update these forward-looking statements, except as required by law.
Puma’s Pharmacy and Distributor Network

Specialty Pharmacy Network:
- Acaria Health
- Accredo
- CVS
- Onco360
- Diplomat
- Biologics

Specialty Distributor Network:
- McKesson
- ASD / Oncology Supply
- Cardinal Health

Sites of Care:
- Academic Hospitals
- Community Hospitals
- Physician Practices
- Other (VA, DoD)

Hub Services

Patients
$48.6 Million Net NERLYNX Revenue in Q1 2020

QUARTERLY NET REVENUE (IN $MM)

Q3 2017: 6.1
Q4 2017: 20.1
Q1 2018: 36
Q2 2018: 50.8
Q3 2018: 52.6
Q4 2018: 61.1
Q1 2019: 45.6
Q2 2019: 53.8
Q3 2019: 53.5
Q4 2019: 58.7
Q1 2020: 48.6
~30% of Patients in Q1 Started NERLYNX at a Reduced Dose

PERCENT OF PATIENT STARTS AT REDUCED DOSE

• Reduced Dose defined as fewer than 6 pills per day
Bottles Sold By Quarter

[Bar chart showing bottles sold by quarter from Q3 2017 to Q1 2020]

- **SP** = Specialty Pharmacy Network, **SD** = Specialty Distributor Network; Bottles defined as 180 Pills
### Rest of World Partnerships – Timelines

<table>
<thead>
<tr>
<th>Region</th>
<th>Partner</th>
<th>Expected Regulatory Approval</th>
</tr>
</thead>
</table>
| Australia / SE Asia            | Specialised Therautics | • March 2019 – Approved in Australia  
|                                |                  |          • December 2019 -- Approved in Singapore                  |
| Israel                         | MEDISON          | • Q2 2020                                                        |
| Canada                         | Knight           | • July 2019 – Approved                                            |
| Greater China                  | CANbridge        | • November 2019 – Approved in Hong Kong  
|                                |                  |          • April 2020 – Approved in China                           |
|                                |                  |          • 2H 2020 – Taiwan                                         |
| Latin America                  | PINT PHARMA       | • September 2019 – Approved in Argentina  
|                                |                  |          • Q2/Q3 2020 – Chile                                      |
|                                |                  |          • 2H 2020 – Ecuador                                        |
|                                |                  |          • 2021– Brazil, Colombia, Mexico, Peru                    |
| Europe                         | Pierre Fabre      | **Launch Timelines**  
| Middle East                    |                  | • Q4 2019 – Germany-Launched                                     |
| North and West Africa          |                  | • Q4 2019 – United Kingdom-Launched                              |
| South Africa                   |                  | • Q4 2019 – Austria-Launched                                     |
| Turkey                         |                  | • Q1 2020 – Sweden Launched                                      |
| South Korea                    | BIXINK           | • End of 2020 – NDA Filing                                       |